Resumen de: US2020299752A1

This disclosure relates to methods of determining quantification conditions for a microorganism and methods of quantifying microorganism concentration in a sample.

Resumen de: US2020300854A1

The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.

Resumen de: US2020297832A1

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.

Resumen de: US2020297825A1

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.

Resumen de: US2020300862A1

A microorganism identification method according to the present invention includes a step of subjecting a sample containing microorganisms to mass spectrometry to obtain a mass spectrum, a step of reading a mass-to-charge ratio m/z of a peak derived from a marker protein from the mass spectrum, and an identification step of identifying which bacteria of serovar of Salmonella genus bacteria the microorganisms contained in the sample contain, based on the mass-to-charge ratio m/z, in which at least one of two types of ribosomal proteins S8 and Peptidylpropyl isomerase is used as the marker protein.

Resumen de: WO2019099578A1

Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.

Resumen de: US2020291460A1

Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacter jejuni, and Campylobacter coli. Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Resumen de: US2020289545A1

The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.

Resumen de: CN111647057A

本发明公开了一种伤寒沙门菌疫苗重组蛋白及其编码基因和它们的应用，该重组蛋白包括如SEQ ID NO.1所示的氨基酸序列。制备方法包括：构建yncD表达质粒，对yncD表达质粒诱导表达和纯化；所述构建yncD表达质粒采用如SEQ ID NO.3和如SEQ ID NO.4所示的引物做PCR，获得yncD基因全序列，连接到表达质粒，得到重组质粒。本发明的重组蛋白包括具有良好免疫原性的靶蛋白，位于沙门菌表面；其是一个涉及铁摄取的TonB依赖性外膜转运体，为细菌体内生存和致病所必需；蛋白的氨基酸序列保守，广泛存在于目前已测序的伤寒沙门菌菌株中，且其基因功能在不同伤寒沙门菌菌株中是一致的，具有良好的免疫原性，对免疫小鼠具有良好的保护效果。

Resumen de: US2020282048A1

Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.

Resumen de: AU2019231316A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

Resumen de: WO2020176809A1

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin" and/or pagP'. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine and/or purine auxotrophs. The bacteria optionally are one or more of asct, purl' and msbB'. The immunostimulatory bacteria, such as Salmonella species, are modified to encode proteins that induce type I interferon (IFN) expression, or that are variants thereof that have increased activity to induce type I IFN expression, or that are variants thereof that result in constitutive expression of type I IFN. The bacteria can encode a modified Stimulator of Interferon Genes (STING) protein from a non-human species, that has lower NF-κΒ signaling activity, and, optionally, higher type I IFN pathway signaling activity, compared to human STING. The bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiti

Resumen de: US2020277605A1

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

Resumen de: WO2020176764A1

Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.

Resumen de: US2019010187A1

An improved, cost effective and shortened process of purification of the capsular polysaccharide of S. Pneumoniae, Group B Streptococcus, H. Influenzae, S. Typhoid and N. meningitidis is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.

Resumen de: CN101175509A

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellulars, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit thatcomprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Resumen de: WO2019136186A2

The inventions described herein relate generally to the methods for monitoring the health of the mammalian gut by checking for whether dysbiotic parameters exceed a threshold level or not. In particular, this invention is directed to the use of parameters which correlate with the level of bifidobacteria, especially Bifidobacterium longum subsp. infantis in the mammalian colon.

Resumen de: WO2020172463A1

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with decoy polypeptides that bind endogenous ligand and block activation of signal transduction cascades associated with cancer cell proliferation and tumor growth. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

Resumen de: WO2020172461A1

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating and to alter tumor metabolism in the tumor microenvironment. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

Resumen de: WO2020172462A1

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with TRAIL to trigger tumor cell apoptosis. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

Resumen de: US2020270613A1

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin− and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine and/or purine auxotrophs. The bacteria optionally are one or more of asst, purI− and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode proteins that induce type I interferon (IFN) expression, or that are variants thereof that have increased activity to induce type I IFN expression, or that are variants thereof that result in constitutive expression of type I IFN. The bacteria can encode a modified Stimulator of Interferon Genes (STING) protein from a non-human species, that has lower NF-κB signaling activity, and, optionally, higher type I IFN pathway signaling activity, compared to human STING. The bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or induce less cell death in immune cells than in other cells. Also provided are methods of i

Resumen de: WO2013012924A2

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface. Microbe-targeting molecules and/or substrates can be regenerated after use by washing with a low pH buffer or buffer in which calcium is insoluble.

Resumen de: WO2019099578A1

Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.

Resumen de: US2020261559A1

Provided herein are vaccine composition comprising an antigen conjugated to a capsid, wherein the capsid comprises wild type or native sequence. Provided herein are also vaccine composition comprising an antigen conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and prevention of pathogenic infections, inflammatory diseases, and neurodegenerative disease, and cancer, among others.

Resumen de: US2020261535A1

The use of flagellin and flagellin related polypeptide for the protection of mammals from the effects of apoptosis is described.